Management of Acute Coronary Syndromes in Patients with Renal Insufficiency

被引：4
作者：
Marenzi, Giancarlo [1 ,2 ]
Assanelli, Emilio [1 ]
Bartorelli, Antonio L. [1 ]
机构：
[1] Univ Milan, IRCCS, Ctr Cardiol Monzino, Inst Cardiol, Milan, Italy
[2] Ctr Cardiol Monzino, Via Parea 4, I-20138 Milan, Italy
来源：
CURRENT CARDIOLOGY REVIEWS | 2006年 / 2卷 / 01期
关键词：
Acute coronary syndromes; renal insufficiency; percutaneous coronary intervention; chronic kidney disease;
D O I：
10.2174/157340306775515371
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Chronic kidney disease (CKD) is highly prevalent in patients with acute coronary syndromes (ACS) and is associated with poor outcomes. The clinical management of patients with CKD who develop ACS is problematic because of the lack of well-designed randomized trials assessing therapeutic strategies in such patients. The almost uniform exclusion of patients with CKD from randomized studies evaluating new targeted therapies for ACS, and concern about further deterioration of renal function and therapy-related toxic effects, may explain the less frequent use of proven medical therapies in this subgroup of high-risk patients. This could contribute to their excessive mortality. The objective of this review is to discuss the unresolved issues and uncertainties regarding recommended medical therapies and interventional strategies in CKD patients who develop an ACS.
引用
收藏
页码：11 / 16
页数：6
相关论文
共 55 条
[1]  
Anavekar NS, 2004, NEW ENGL J MED, V351, P1285, DOI 10.1056/NEJMoa041365
[2]  
[Anonymous], 1988, LANCET, V2, P349
[3]  
[Anonymous], 1986, LANCET, V1, P397
[4]   Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction [J].
Beattie, JN ;
Soman, SS ;
Sandberg, KR ;
Yee, J ;
Borzak, S ;
Garg, M ;
McCullough, PA .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 37 (06) :1191-1200
[5]   Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction [J].
Berger, AK ;
Duval, S ;
Krumholz, HM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (02) :201-208
[6]   The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: The Do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial [J].
Berger, PB ;
Best, PJM ;
Topol, EJ ;
White, J ;
DiBattiste, PM ;
Chan, AW ;
Kristensen, SD ;
Herrmann, HC ;
Moliterno, DJ .
AMERICAN HEART JOURNAL, 2005, 149 (05) :869-875
[7]   Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation [J].
Bertrand, ME ;
Simoons, ML ;
Fox, KAA ;
Wallentin, LC ;
Hamm, CW ;
McFadden, E ;
De Feyter, PJ ;
Specchia, G ;
Ruzyllo, W .
EUROPEAN HEART JOURNAL, 2002, 23 (23) :1809-1840
[8]   The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions [J].
Best, PJM ;
Lennon, R ;
Ting, HH ;
Bell, MR ;
Rihal, CS ;
Holmes, DR ;
Berger, PB .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (07) :1113-1119
[9]   Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes [J].
Bhatt, DL ;
Topol, EJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (12) :1549-1558
[10]   PHARMACOKINETIC STUDIES OF STANDARD UNFRACTIONATED HEPARIN, AND LOW-MOLECULAR WEIGHT HEPARINS IN THE RABBIT [J].
BONEU, B ;
CARANOBE, C ;
CADROY, Y ;
DOL, F ;
GABAIG, AM ;
DUPOUY, D ;
SIE, P .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1988, 14 (01) :18-27
123456